Phase II Study of Everolimus in Metastatic Malignant Melanoma (NCCTG‐N0377, Alliance)

LESSONS LEARNED. Everolimus does not have sufficient activity to justify its use as single agent in metastatic melanoma. Patients treated with 10 mg per day dose were most likely to require dose reductions. Everolimus appeared to reduce the numbers of regulatory T cells in approximately half of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Vera Aguilera, Jesus, Rao, Ravi D., Allred, Jacob B., Suman, Vera J., Windschitl, Harold E., Kaur, Judith S., Maples, William J., Lowe, Val J., Creagan, Edward T., Erickson, Lori A., Markovic, Svetomir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2018
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156180/
https://www.ncbi.nlm.nih.gov/pubmed/29666297
http://dx.doi.org/10.1634/theoncologist.2018-0100

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156180/
https://www.ncbi.nlm.nih.gov/pubmed/29666297
http://dx.doi.org/10.1634/theoncologist.2018-0100

Ejemplares similares